Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice
- PMID: 21954284
- PMCID: PMC3250305
- DOI: 10.1189/jlb.0311177
Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice
Abstract
MDSCs are a group of cells with potent immune-suppressive activity. These cells accumulate in many pathologic conditions and play a major role in the regulation of immune responses. The nature of MDSC remains highly debatable. In cancer, most MDSCs are represented by cells with granulocytic phenotype and morphology, G-MDSC. The relationship between G-MDSCs and Neu remains unclear. In this study, we have found that G-MDSCs, from tumor-bearing, and Neu, from tumor-free, mice share a common morphology and phenotype. However, in contrast to Neu, a substantial proportion of G-MDSCs expressed M-CSFR and a CD244 molecule. Neu had significantly higher phagocytic activity, expression of lysosomal proteins, and TNF-α than corresponding G-MDSCs, which had significantly higher activity of arginase, MPO, and ROS. In contrast to G-MDSC, neither rested nor mobilized Neu suppressed T cells. G-MDSC survived 2 days in culture in the presence of GM-CSF and within 24 h, became phenotypic and functionally similar to Neu. Tumor-associated G-MDSC shared most characteristics of splenic G-MDSC, rather then Neu. These data suggest that in cancer, despite morphological and phenotypic similarities, G-MDSCs are functionally distinct from Neu and are comprised of pathologically activated precursors of Neu.
Figures
Similar articles
-
Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.Eur J Immunol. 2018 Mar;48(3):532-542. doi: 10.1002/eji.201746976. Epub 2017 Dec 8. Eur J Immunol. 2018. PMID: 29120053 Free PMC article.
-
6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.Cancer Immunol Immunother. 2015 Aug;64(8):1033-46. doi: 10.1007/s00262-015-1702-8. Epub 2015 May 16. Cancer Immunol Immunother. 2015. PMID: 25982370 Free PMC article.
-
Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.J Immunol. 2012 Dec 15;189(12):5602-11. doi: 10.4049/jimmunol.1201018. Epub 2012 Nov 14. J Immunol. 2012. PMID: 23152559
-
On the origin of myeloid-derived suppressor cells.Oncotarget. 2017 Jan 10;8(2):3649-3665. doi: 10.18632/oncotarget.12278. Oncotarget. 2017. PMID: 27690299 Free PMC article. Review.
-
Myeloid-derived suppressor cells in malignant melanoma.J Dtsch Dermatol Ges. 2014 Nov;12(11):1021-7. doi: 10.1111/ddg.12411. Epub 2014 Sep 28. J Dtsch Dermatol Ges. 2014. PMID: 25263083 Review. English, German.
Cited by
-
Ablation of NLRP3 inflammasome rewires MDSC function and promotes tumor regression.Front Immunol. 2022 Aug 10;13:889075. doi: 10.3389/fimmu.2022.889075. eCollection 2022. Front Immunol. 2022. PMID: 36032139 Free PMC article.
-
Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer.J Immunother Cancer. 2020 Oct;8(2):e000609. doi: 10.1136/jitc-2020-000609. J Immunother Cancer. 2020. PMID: 33051339 Free PMC article. Review.
-
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.Adv Cancer Res. 2015;128:95-139. doi: 10.1016/bs.acr.2015.04.002. Epub 2015 May 12. Adv Cancer Res. 2015. PMID: 26216631 Free PMC article. Review.
-
The elevated pretreatment platelet-to-lymphocyte ratio predicts poor outcome in nasopharyngeal carcinoma patients.Tumour Biol. 2015 Sep;36(10):7775-87. doi: 10.1007/s13277-015-3505-0. Epub 2015 May 6. Tumour Biol. 2015. PMID: 25944165
-
Impact of TCM on Tumor-Infiltrating Myeloid Precursors in the Tumor Microenvironment.Front Cell Dev Biol. 2021 Mar 4;9:635122. doi: 10.3389/fcell.2021.635122. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33748122 Free PMC article. Review.
References
-
- Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., Bronte V. (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22, 238–244 - PubMed
-
- Shojaei F., Wu X., Malik A. K., Zhong C., Baldwin M. E., Schanz S., Fuh G., Gerber H. P., Ferrara N. (2007) Tumor refractoriness to anti-VEGF treatment is mediated by CD11b(+)Gr1(+) myeloid cells. Nat. Biotechnol. 25, 911–920 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous